The drug abuse problem in general and the wide spread use of marijuana in particular has focused attention on the chemistry and pharmacology of this plant (Cannabis Sativa). Although rapid advances have been made in the chemistry and pharmacology of this class of compounds, the mechanisms involved in producing the various central nervous effects (CNS) have not been established. The long term goal of our synthetic program is to develop delta9-tetrahydrocannabinol (THC) analogs which will prove to be useful tools in elucidating the mechanism of action of cannabinoids. The present emphasis will be directed toward: (1) designing new analogs which will clarify the cannabinoid pharmacophore and (2) designing analogs which are antagonists. In addition the goal of developing cannabinoid analogs with a limited pharmacological profile represents a continuation from the current grant. The new analogs will be modelled after THCs and structural hybrids containing features of both THCs and aminoalkylindoles.
Our specific aims are to synthesize (1) novel aminoalkylindoles carrying at position 4 of the indole, side chains which are optimum for activity in THCs; (2) delta8/delta9-THCs with side chain containing double or triple bonds, and phenyl group with trifluoromethyl substituent at various positions; (3) the corresponding amino and alkylamino compounds in both the R and S series as an extension of the ongoing work on 2',3',4'-side chain hydroxylated delta9-THCs' (4) delta8-THC analogs with the N-bis(2- chloroethyl) functional group present at 3'- and 5'-positions as potential receptor probes and antagonists; (5) novel ester and amide derivatives of 9-nor-9-carboxy-delta9-THC in both the (-)- and the (+)- series. The synthesis of these analogs and their subsequent biological evaluation could provide us with new knowledge about Structure Activity Relationships (SAR) in cannabinoids; it could lead to the discovery of an antagonist which would help in the search for an endogenous ligand for cannabinoid activity and thus result in a rapid advance in this field. The discovery of an antagonist will also prove to be a valuable tool in assessing the dependence producing properties of delta9-THC. The proposed study will give a deeper understanding, at least in part, of the mechanisms involved in the pharmacological action of these compounds and will help to combat the drug abuse problem which has had profound effects on our present day society.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA005488-13
Application #
6174588
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Hillery, Paul
Project Start
1988-06-01
Project End
2002-06-30
Budget Start
2000-07-19
Budget End
2001-06-30
Support Year
13
Fiscal Year
2000
Total Cost
$267,704
Indirect Cost
Name
Organix, Inc.
Department
Type
DUNS #
City
Woburn
State
MA
Country
United States
Zip Code
01801
Nguyen, Thuy; Li, Jun-Xu; Thomas, Brian F et al. (2017) Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. Med Res Rev 37:441-474
Ghosh, Sudeshna; Wise, Laura E; Chen, Yugang et al. (2013) The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci 92:498-505
Wiley, Jenny L; Marusich, Julie A; Zhang, Yanan et al. (2012) Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice. Eur J Pharmacol 695:62-70
Bátkai, Sándor; Mukhopadhyay, Partha; Horváth, B?la et al. (2012) ?8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. Br J Pharmacol 165:2450-61
Wiley, Jenny L; Selley, Dana E; Wang, Pinglang et al. (2012) 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB?) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB?, non-CB? mechanism. J Pharmacol Exp Ther 340:433-44
Ramesh, Divya; Ross, Gracious R; Schlosburg, Joel E et al. (2011) Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339:173-85
Kinsey, Steven G; Mahadevan, Anu; Zhao, Bingjun et al. (2011) The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology 60:244-51
Wiley, Jenny L; Breivogel, Christopher S; Mahadevan, Anu et al. (2011) Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol 651:96-105
Kinsey, Steven G; Nomura, Daniel K; O'Neal, Scott T et al. (2011) Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 338:795-802
Mao, Yingying; Zhang, Ming; Tuma, Ronald F et al. (2010) Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice. J Cereb Blood Flow Metab 30:1044-52

Showing the most recent 10 out of 12 publications